State-of-the-Art Clinical Symposium
About the Event
Date:To Be Announced
Location:To Be Announced
Credit:Credit TBA
On Demand:Not Available
During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders will deliver a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, in an environment conducive to dialogue and networking.
Target Audience
Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most up-to-date evidence-based treatment approaches in the management of rheumatic diseases
- Identify and describe recent scientific and clinical advances regarding the pathogenesis of rheumatology
See information from the 2024 meeting in the State-of-the-Art Clinical Symposium 2024 section below.
Program Schedule & Syllabi
To Be Announced
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
Registration Fees
To Be Announced
Hotel and Travel
To Be Announced
Corporate Support
The American College of Rheumatology thanks our corporate supporters and partners for their commitment to advancing rheumatology by supporting ACR and ARP programs and initiatives.
See current supporters, guidelines, and benefits of supporting the ACR.
CME
Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
Designation Statement
The ACR designates this blended learning activity encompassing live and on demand activity for a maximum of (coming soon) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by (coming soon).
MOC
MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to (coming soon) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by (coming soon).
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relatioships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
- SOTA 2025 Financial Relationships Disclosures (coming soon)
- SOTA 2025 Mitigation Spreadsheet (coming soon)
- View ACR's ACCME disclosure practices
See 2024 disclosures in the 2024 meeting section below.
During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders delivered a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, in an environment conducive to dialogue and networking.
Target Audience
Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the most up-to-date evidence-based treatment approaches in the management of rheumatic diseases
- Identify and describe recent scientific and clinical advances regarding the
Program Schedule & Syllabi
State-of-the-Art Clinical Symposium 2024 Full Schedule
Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.
CME
Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
Designation Statement
The ACR designates this blended learning activity encompassing live and on demand activity for a maximum of 9.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by December 31, 2024.
MOC
MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.
After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.
MOC points must be claimed by December 31, 2024.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relatioships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
SOTA 2024 Financial Relationships Disclosures
SOTA 2024 Mitigation Spreadsheet
View ACR's ACCME disclosure practices
*All of the relevant financial relationships listed for these individuals have been mitigated.